Trials / Completed
CompletedNCT03749109
Quinagolide Vaginal Ring on Lesion Reduction Assessed by MRI in Women With Endometriosis/Adenomyosis
A Randomised, Double-blind, Placebo-controlled, Proof-of-mechanism Phase 2 Trial Investigating the Effect of Quinagolide Extended-release Vaginal Ring on Reduction of Lesions Assessed by High-resolution Magnetic Resonance Imaging in Women With Endometrioma, Deep Infiltrating Endometriosis, and/or Adenomyosis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 67 (actual)
- Sponsor
- Ferring Pharmaceuticals · Industry
- Sex
- Female
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Not accepted
Summary
This will be a randomized, double-blind, placebo-controlled, proof-of-mechanism phase 2 trial investigating the effect of quinagolide extended-release vaginal ring on reduction of lesions assessed by high-resolution magnetic resonance imaging in women with endometrioma, deep infiltrating endometriosis, and/or adenomyosis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Quinagolide 1080 µg | Vaginal ring containing Quinagolide 1080 µg for daily releases |
| DRUG | Placebo | Matching placebo |
Timeline
- Start date
- 2019-08-19
- Primary completion
- 2021-06-21
- Completion
- 2021-07-18
- First posted
- 2018-11-21
- Last updated
- 2023-08-07
- Results posted
- 2022-09-07
Locations
11 sites across 4 countries: Denmark, Germany, Italy, Poland
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03749109. Inclusion in this directory is not an endorsement.